Background-Many hospitalized medically ill patients are at risk of venous thromboembolism (VTE). Risk factors include prior VTE, older age, immobility, obesity, cardiac or respiratory failure, and cancer (at-risk patients). Although guidelines recommend use of VTE prophylaxis for at-risk patients, many may not receive it. Methods and Results-Using a database linking admission records from >150 US hospitals to health insurance claims, we identified people ≥40 years of age, hospitalized from 2003 to 2008. We excluded patients who: (1) were treated for VTE or hospitalized in the previous 30 days; (2) were admitted for traumatic injury or surgery; (3) had hypercoagulability at admission; or (4) received therapeutic dosages of low-molecular weight heparin, unfractionated heparin, or fondaparinux at admission. We examined the use of VTE prophylaxis (both pharmacological and nonpharmacological) on day 1 or 2 in hospital among at-risk patients; predictors of receipt of prophylaxis were examined using multivariate logistic regression. The study population consisted of 49 948 patients, of whom 34 374 (69%) were at risk. Only 18% of at-risk patients received VTE prophylaxis on day 1 or 2 in hospital, typically with low-molecular weight heparin (56% of patients receiving prophylaxis), intermittent pneumatic compression (25%), warfarin (16%), or graduated compression stockings (11%). Use of prophylaxis exceeded 25% only in patients admitted from nursing homes and those with prior VTE. Although there were several significant predictors of receipt of VTE prophylaxis, model discrimination was relatively poor (C-statistic=0.61). Conclusion-The majority of at-risk hospitalized medically ill patients do not receive VTE prophylaxis. (Circ Cardiovasc Qual Outcomes. 2013;6:75-82.)
D
eep vein thrombosis and pulmonary embolism, together referred to as venous thromboembolism (VTE), are important causes of disability and death in hospitalized patients. Risk of VTE has been reported to be substantially higher among hospitalized patients (961 cases per 100 000 person-years) compared with people residing in the community (7.1 cases per 100 000 person-years). 1 Medical and surgical admissions account for roughly equal numbers of cases of VTE. Although risk is substantially higher among patients undergoing major surgery, the number of hospitalizations for medical illness is much greater than the number of admissions for surgery. 2 For many years, the American College of Chest Physicians (ACCP) has recommended VTE prophylaxis for large groups of medical and surgical patients for whom the benefits seem to outweigh the risks (chiefly, bleeding because of anticoagulation). In the 2008 ACCP guidelines, anticoagulant prophylaxis was recommended for acutely ill medical patients admitted to the hospital with congestive heart failure or severe respiratory disease or who are confined to bed and have ≥1 additional risk factors, including active cancer, previous VTE, sepsis, acute neurological disease, or inflammatory bowel disease, in the absence of contraindications (chiefly, excessive risk of bleeding). 3 These guidelines also recommended that most patients admitted to critical care units and those with ischemic stroke receive VTE prophylaxis. Mechanical prophylaxis was recommended for those with contraindications to anticoagulants. (Note: The recently released 2012 ACCP guidelines 4 distinguish between patients at increased risk and those at low risk of thrombosis and recommend use of anticoagulants only among the former; these guidelines were released after our study was completed.)
Several recent studies indicate that levels of adherence to these recommendations may be low in the United States. Reported percentages of hospitalized medically ill patients in the United States who meet ACCP guidelines and receive VTE prophylaxis range from 36% to 64%; reported percentages receiving appropriate prophylaxis (based on type, dose, and duration) are much lower (ie, <10%). [5] [6] [7] [8] Although the aforementioned studies focused on patients with ≥1 risk factors for VTE based on ACCP guidelines, many other risk factors also have been identified (although their contribution to VTE risk is believed to be less than those of characteristics designated as risk factors by the ACCP). 6, 9 In this study, we examine the extent of use of VTE prophylaxis in hospitalized medically ill patients in the United States, considering patients with both ACCP-designated risk factors and other established risk factors.
Methods

Data Source
This study used a novel database linking detailed information on hospital admissions (from the Thomson Reuters Hospital Drug Database [admissions database]) to health insurance claims (from the Thomson Medstat MarketScan Database [claims database]). Information in the admissions database is extracted from the decision-support and cost-accounting systems of ≈150 US, short-term, general, acutecare hospitals, comprising ≈3 million discharges annually. For each admission, the database includes (but is not limited to) information on patient demographics, principal and secondary diagnosis codes (in International Classification of Diseases, Ninth Edition, Clinical Modification [ICD-9-CM] format), principal and secondary procedure codes (in ICD-9-CM format), primary payer, length of stay, drug utilization, discharge status and destination, department charge detail, and total inpatient charges.
The claims database is composed of paid facility, provider, and retail pharmacy claims from a variety of private US health plans, providing health insurance coverage to >10 million people annually, and contains information on patient demographics and eligibility for health benefits, inpatient and outpatient diagnoses (in ICD-9-CM format), inpatient and outpatient procedures (in ICD-9-CM, Physician's Current Procedural Terminology, Fourth Edition, and Health Care Financing Administration Common Procedure Coding System formats), and drugs dispensed through retail pharmacies (in National Drug Code format). Dates of service are available for all drugs and medical services.
All patient-identifying information was either fully encrypted or removed from the study database; it is therefore compliant with the Health Insurance Portability and Accountability Act of 1996 and federal guidance on Public Welfare and the Protection of Human Subjects. Per the Code of Federal Regulations (45 CFR 45 §46.101), institutional review board review was not needed for a study of this nature, because "subjects cannot be identified, directly or through identifiers linked to the subjects."
Sample Selection
Using the admissions database, we identified all people ≥40 years of age who were hospitalized between January or traumatic injury (ICD-9-CM diagnosis codes 800.XX-969.XX), as well as those who underwent major surgery (ICD-9-CM procedure codes 01.XX-86.99, excluding codes for common procedures, such as bronchoscopy, cardiac catheterization, and spinal tap). Among these hospitalized patients, we then ascertained those who also were represented in the claims database (the 2 data systems are completely independent) and linked information for all such people. The resulting database therefore contained detailed information on hospital stays (including VTE prophylaxis received) for a cohort of hospitalized medically ill patients, information on their demographic and clinical characteristics and medical treatment in the period preceding hospital admission, and information on outcomes and treatment after hospital discharge.
After linkage of the 2 databases for these identified patients, we excluded patients from the study sample who: (1) did not have complete data available for at least 6 months before their date of hospital admission (index date); (2) were treated for VTE or hospitalized for any reason within the previous 30 days; (3) were admitted to the hospital because of traumatic injury; (4) had a hypercoagulability disorder (ICD-9-CM diagnosis codes 286.3, 286.6, 289.8, 289.9) at admission; or (5) received low-molecular weight heparin (LMWH; ie, enoxaparin, dalteparin, tinzaparin), unfractionated heparin, or fondaparinux at therapeutic dosages on hospital day 1 or 2. Therapeutic dosages of these agents were defined as follows: enoxaparin, >40 mg/day; dalteparin, >5000 IU/day; tinzaparin, ≥7000 IU/day; unfractionated heparin, >15 000 IU/day; and fondaparinux, ≥5 mg/day.
Measures
VTE prophylaxis was defined to include both pharmacological and nonpharmacological modalities. The former category consisted of LMWH, unfractionated heparin, and fondaparinux at prophylactic dosages (enoxaparin, ≤40 mg/day; dalteparin, ≤5000 IU/day; tinzaparin, <7000 IU/day; unfractionated heparin, ≤15 000 IU/day; fondaparinux, <5 mg/day) or warfarin at any dose. (Although warfarin is not recommended in the ACCP guidelines for prevention of VTE in medically ill patients, many physicians may believe that additional prophylactic measures are unnecessary in patients who are already receiving warfarin at the time of admission [eg, because of atrial fibrillation]. These patients were retained in the study sample to ensure that it is reflective of the overall population of hospitalized medically ill patients.) Nonpharmacological prophylaxes were defined to include graduated compression stockings and intermittent pneumatic compression devices. Patients were considered to have received VTE prophylaxis at admission if they had evidence of receipt of any of the above-mentioned agents or modalities on either day 1 or day 2 in the hospital. 10 Patients who began VTE prophylaxis later
WHAT IS KNOWN
• Although venous thromboembolism (VTE) risk is substantially higher in patients undergoing major surgery, medical and surgical admissions account for roughly equal numbers of VTE cases.
• For many years, guidelines have recommended that medically ill patients receive VTE prophylaxis while in the hospital, but rates of use remain relatively low.
WHAT THE STUDY ADDS
• Our study suggests that fewer than one fifth of all atrisk medically ill hospitalized patients receive VTE prophylaxis within the first 48 hours in the hospital.
• Rates of use of VTE prophylaxis were only modestly higher in at-risk patients than among those without any identifiable risk factors for VTE (13.7%).
• Our findings highlight the need for a better understanding of why rates of VTE prophylaxis remain relatively low in medically ill hospitalized patients and whether the new American College of Chest Physicians guidelines will improve compliance, especially among at-risk patients.
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http://circoutcomes.ahajournals.org/ Downloaded from during their hospital stays were considered not to have received VTE prophylaxis at admission. Due to limitations in study data, examination of postdischarge use of VTE prophylaxis was limited to pharmacotherapy. Patients were followed for postdischarge receipt of VTE prophylaxis to 180 days after index admission, health plan disenrollment, or the end of the study period, whichever occurred first.
Analyses
We examined the demographic and clinical characteristics of study subjects as of the index date in terms of their age, sex, and presence of contraindications for VTE prophylaxis, using frequency distributions for categorical variables and means and SD for continuous variables.
We examined the use of VTE prophylaxis alternatively among all patients meeting ACCP criteria (8th edition) and those with any of 20 designated risk factors for VTE as follows: (1) acute coronary syndrome; (2) cancer; (3) chronic obstructive pulmonary disease; (4) congestive heart failure; (5) inflammatory bowel disease; (6) ischemic stroke; (7) . Presence of the above-mentioned risk factors was ascertained using admission source codes (nursing home residence), prescriptions dispensed at retail pharmacies during the 6-month period preceding admission (erythropoietic stimulating agents, hormone replacement therapy, oral contraceptives), and ICD-9-CM codes associated with the index admission or encounters during the 180-day preadmission period. Acute coronary syndrome, ischemic stroke, and thrombophilia were only considered risk factors if these were noted during the index admission. Patients with any of the above-listed 20 VTE risk factors were designated at-risk.
Predictors of receipt of VTE prophylaxis were examined using multivariate logistic regression. Results are reported as odds ratios (ORs) with corresponding 95% confidence intervals (CIs) and P values. ORs represent the likelihood that patients with a particular risk factor or characteristic received VTE prophylaxis. Model discrimination was evaluated using the C-statistic, with values approaching 1 for perfectly discriminating models. The analyses were performed using SAS V9.2 (SAS Institute, Inc., Cary, NC).
Results
Patient Characteristics
The study population consisted of 49 948 patients. Fifty-six percent of patients were ≥65 years of age, and mean age (SD) was 67 (13) years (Table 1) . One-half of all patients (51.6%) had stays in hospital of ≥3 days. Approximately 7% of patients had contraindications to VTE prophylaxis. More than 68% of index admissions (n=34 374) involved patients with ≥1 risk factors for VTE (ie, at-risk patients), and 54% of index admissions (n=27 075) involved patients with an ACCP indication for prophylaxis. The most prevalent VTE risk factors included chronic obstructive pulmonary disease (19.5%), congestive heart failure (16.6%), intensive care unit admission (15.6%), acute coronary syndrome (14.2%), and cancer (14.0%).
Use of VTE Prophylaxis
Only 18% of at-risk patients received in-hospital prophylaxis within 48 hours of admission. Among patients receiving VTE prophylaxis, 64% received pharmacological prophylaxis, 31% received nonpharmacological prophylaxis, and 5% received both. The most frequently used prophylaxes were LMWH (56% of all patients receiving VTE prophylaxis), followed by intermittent pneumatic compression (25%), warfarin (16%), and graduated compression stockings (11%). The rate of use of VTE prophylaxis was identical (18%) in the subset of patients with an ACCP indication for prophylaxis (n=27 075; 54% of study sample). The rate of use of prophylaxis in patients without any of the designated risk factors for VTE or an ACCP indication for prophylaxis (n=15 574; 31% of study sample) was 13.7%.
The Figure shows the percentage of patients receiving prophylaxis by VTE risk factor. Rates of use of in-hospital VTE prophylaxis ranged from 31.6% for patients admitted from nursing homes to 12.1% for patients with inflammatory bowel disease. Prophylaxis use exceeded 25% only in patients with a history of VTE and those admitted to hospital from nursing homes. Cancer patients had below-average rates of VTE prophylaxis (17.4%), along with patients with acute coronary syndrome and those who received erythropoietic stimulating agents or hormone replacement therapy before hospital admission. Few patients (1.7%) who received VTE prophylaxis during their index admission received postdischarge VTE prophylaxis, and use was limited to LMWH.
There were several statistically significant predictors of VTE prophylaxis in multivariate analyses ( 
Discussion
We found that use of prophylaxis within 48 hours of hospital admission was quite low in medically ill patients with any of 20 designated risk factors for VTE-only 18%. A similar rate was observed among patients with ACCP-designated risk factors. The percentage of patients receiving VTE prophylaxis was only modestly higher in both of these groups than among patients without any identified risk factors for VTE (13.7%).
At least one other study has reported similar findings. The CURVE (Multi-Centre Chart Audit of the Utilization of Risk Assessment and of Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Patients in Canada) study, which was based on a multicenter chart audit, reported that 23% of hospitalized medically ill patients in Canada received VTE prophylaxis and that 16% of these patients received appropriate prophylaxis. 11 Another study similar in design to ours, however, reported substantially higher rates of VTE prophylaxis in hospitalized medically ill patients (35.7%). 8 Like our study, Rothberg et al 8 also used a large US inpatient database and required that VTE prophylaxis (pharmacological or mechanical) be initiated during the first 2 days of hospitalization. In contrast to our study, however, they excluded patients with hospital stays ≤2 days, and the proportion of their patients treated in teaching hospitals was almost 3-fold higher (33.6% versus 12.7% in our study). The Rothberg et al operational definition of the ACCP guidelines also was different from ours (eg, they included patients with urinary tract infections and respiratory failure, whereas we did not; we included patients admitted to an intensive care unit, whereas they did not; we identified patients with risk factors for VTE using information on conditions present either at admission or during the 180-day period preceding it, whereas they identified risk factors using only the former). We do not know the extent to which these various differences actually contributed to the difference in findings.
We note that the proportion of eligible (ie, at-risk) patients receiving VTE prophylaxis in both the study by Rothberg et al 8 and ours was much lower than that reported in the 2 recent studies based on review of medical records: ENDORSE (Epidemiologic International Day for the Evaluation of Patients at Risk for Venous Thromboembolism in the Acute Hospital Care Setting) and IMPROVE. These studies reported that 64% and 61%, respectively, of medically ill hospitalized patients in the United States received VTE prophylaxis. 5, 6 We suspect that one explanation for much higher rates of use in these 2 studies is the ability of investigators to assess immobility (confinement to bed), which neither Rothberg et al nor we could do given limitations in the data. In addition, both ENDORSE and IMPROVE (International Medical Prevention Registry on Venous Thromboembolism) counted patients as having received VTE prophylaxis if it was administered at any time during hospitalization. We also note that both studies included a larger proportion of academic hospitals than was true in our study (44% of hospitals participating in ENDORSE were academic, 67% of hospitals participating in IMPROVE had residency teaching programs, whereas only 13% of the hospitals in our study had such programs). Both the studies also were multinational and included comparatively few patients from only a limited number of US hospitals.
Explanations for the comparable rates of use of VTE prophylaxis that we observed among patients with ACCP-designated risk factors versus other risk factors not listed by the ACCP, as well as for patients without any identified risk factors for VTE, are not as obvious. We do note, however, that in the IMPROVE study, the percentage of patients without ACCPdesignated risk factors who received VTE prophylaxis was 46% (a percentage calculated by us from data in the report), which is <61% of US patients with risk factors designated by ACCP, but nonetheless quite high. 5 (IMPROVE does not provide a description of the risk factors, if any, among patients without ACCP-listed risk factors.) The ENDORSE study reported that 29% of patients at low risk of VTE (ie, without ACCP-listed risk factors) received prophylaxis and that only 50% of these patients had recognized risk factors for VTE either before hospital admission (eg, chronic obstructive pulmonary disease or congestive heart failure) or during hospitalization (eg, immobilization, central venous catheter). 6, 12 It thus seems that in actual practice, clinicians consider a large variety of risk factors when choosing whether to administer prophylaxis. In the case of patients in our study who had none of the listed risk factors for VTE, there may have been various reasons that they received prophylaxis. For example, some may have been immobilized before admission, some may have continued prophylaxis initiated postoperatively during a hospitalization that occurred >30 days before admission, some may have had a history of VTE or other prehospital risk factors recorded before our study's 180-day look-back period, and some may have been obese but did not have this diagnosis recorded. Investigation of the reasons that patients without apparent risk factors received prophylaxis is beyond the scope of our study but would be of considerable interest. Three randomized, placebo-controlled trials, as well as a background review prepared for an American College of Physicians clinical guidance document, have called into question some of the guidance provided by the 2008 ACCP guidelines. [13] [14] [15] [16] [17] In a trial conducted in China, India, Korea, Malaysia, Mexico, the Philippines, and Tunisia, 8307 acutely ill hospitalized medical patients, ≥40 years of age, were randomly assigned to receive in-hospital prophylaxis with enoxaparin (40 mg daily) or placebo; both groups received graduated compression elastic stockings. 13 In addition to their primary qualifying diagnosis (most patients [95%] had diagnosis of either heart failure or severe systemic infection), study subjects had to have at least one of the following additional risk factors for VTE: chronic pulmonary disease, age ≥60 years, obesity, or history of VTE. Rates of all-cause mortality at 30 days, the primary outcome in the trial, were 4.9% for enoxaparin and 4.8% for placebo (risk ratio, 1.0; 95% CI, 0.8-1.2; P=0.83). Corresponding rates of major bleeding were 0.4% and 0.3% (risk ratio, 1.4; CI, 0.7-3.1; P=0.35).
Hull et al 14 conducted a randomized controlled trial of extended prophylaxis with enoxaparin in 5963 acutely ill medical patients aged ≥40 years, all of whom received 10 days of enoxaparin prophylaxis and then were randomly assigned to receive enoxaparin or placebo for an additional 28 days. At study entry, all patients were considered likely to have their mobility restricted for at least 3 days, and they were further divided into those who were anticipated to have bathroom privileges versus not. Although the incidence of VTE (mostly symptomatic deep vein thrombosis) was lower among patients who received extended prophylaxis (2.5% versus 4% for placebo [absolute risk difference favoring enoxaparin, −1.53%; 95% CI, −2.54% to −0.52%]), their risk of major bleeding was higher (0.8% versus 0.3%, respectively [absolute risk difference favoring placebo, 0.51; 0.12-0.89]). There was no significant difference in mortality between the 2 groups. In subgroup analyses, reduction in the incidence of VTE was found to be limited to women, patients >75 years of age, and those without bathroom privileges.
Goldhaber et al 15 compared 30 days of apixaban therapy with in-hospital use of enoxaparin (6-14 days) among 6528 patients with selected medical diseases (heart failure, 39%; acute respiratory failure, 37%; infection without septic shock, 21.5%) plus 1 additional risk factor for VTE. 15 Patients who were randomly assigned to receive in-hospital enoxaparin also received an oral placebo at the time of hospital discharge. There was no difference between the 2 treatment groups in the primary end point, which was the 30-day composite of death related to VTE, symptomatic pulmonary embolism, deep vein thrombosis, or asymptomatic proximal leg deep-vein thrombosis, as detected by ultrasound on day 30. The incidence of major bleeding was higher among patients who received apixaban (relative risk, 2.58; 95% CI, 1.02-7.24).
Lederle et al 16 recently reviewed randomized trials of anticoagulant prophylaxis-specifically, heparin, LMWH, or fondaparinux-in medically ill patients and reported that although available evidence did not indicate that it reduced all-cause mortality, risk of pulmonary embolism was lower among patients receiving the above-mentioned prophylaxes (OR, 0.69; 0.52-0.90) (although there was evidence of publication bias), whereas risk of bleeding events was higher (OR, 1.34; 1.08-1.66). On the basis of this review and other data, the American College of Physicians disseminated clinical practice guidelines in 2011 concerning VTE prophylaxis in hospitalized medical patients. 17 These guidelines are of a Primarily, they recommend distinguishing increased-risk and low-risk patients on the basis of a specific risk-assessment instrument-the Padua Prediction Score-and administering anticoagulant prophylaxis only to those at increased risk. Patients with a cumulative score ≥4 points are considered to be high risk. Four items each confer a score of 3 points: active cancer, previous VTE, reduced mobility, and a known thrombophilic condition. Recent trauma/surgery (≤1 month) receives 2 points and each of the following 1 point: ≥70 years of age, heart and respiratory failure, acute myocardial infarction or ischemic stroke, acute infection and rheumatologic disorder, body mass index ≥30, and ongoing hormonal treatment. Many patients for whom anticoagulant thromboprophylaxis was recommended in 2008 would not necessarily qualify according to the 2012 guidelines, especially those with heart failure or severe respiratory disease. In 2008, anticoagulant prophylaxis was recommended for such patients on the basis of these diagnoses alone, whereas these diagnoses only receive 1 point each toward the calculation of a risk score in the 2012 guidelines. The difference the new guidelines will make in actual clinical practice is unclear, however. Although patients with heart failure and severe respiratory disease will not necessarily meet the 2012 criteria, we suspect that many such patients may have restricted mobility ordered for the first few days of their hospitalization.
Our study has several limitations. As is the case with all studies based on administrative databases, errors of commission and omission are always a concern, especially regarding the ascertainment of acute and chronic medical conditions using ICD-9-CM diagnosis codes. Confinement to bed (ie, immobility), for example, is not a codable medical condition, and body mass index is not among the available data elements. The absence of such information, especially with respect to immobility, is a distinct limitation of our study.
In addition, ICD-9-CM diagnosis codes are not dated and represent conditions that were either present at admission or developed during hospitalization. With many chronic conditions (eg, osteoarthritis, diabetes mellitus, atherosclerosis), it is a reasonable assumption that they were present at admission. With acute conditions, however, it may be impossible in many instances to determine whether they were present at admission or, conversely, developed in hospital. Among the risk factors for VTE that we used in our analysis were both chronic and acute conditions. To the extent that we incorrectly designated some patients as high risk based on an acute condition that in fact was not present at admission, we may have imparted a downward bias to our estimates of the use of VTE prophylaxis in these patients (and a corresponding upward bias to estimated prophylaxis rates among those who were deemed not to be at elevated risk).
There also is anecdotal evidence suggesting that enoxaparin sometimes may be used prophylactically in medically ill patients at a dose of 30 mg twice daily rather than 40 mg once daily (the only approved dose in the United States in this patient population). To the extent that this practice exists, we may have underestimated the extent to which enoxaparin is administered with prophylactic intent. (We note, however, that if the higher dose increases risk of bleeding versus a dose of 40 mg once daily, it could be argued that perhaps these patients did not receive appropriate prophylaxis.)
In summary, our findings are consistent with prior research reporting that VTE prophylaxis is substantially underused in at-risk hospitalized medically ill patients in the United States. Our results highlight the need for further efforts to increase use of prophylaxis in this patient population. We note in defense of clinicians, however, that the nonspecific nature of the ACCP recommendations may be one factor inhibiting greater uptake of prophylaxis. Many terms in the 2008 guidelines, for example, are not specifically defined (eg, severe respiratory disease, confinement to bed). Clinicians also may recognize certain exceptions to these recommendations, such as patients admitted for terminal care. Furthermore, recent studies highlight the complexity of issues related to thromboprophylaxis and create uncertainty as to its role in medically ill patients. The 2012 ACCP guidelines reflect a more cautious approach, distinguishing increased-risk and low-risk patients, and recommend anticoagulant prophylaxis only for the former group. Additional research is clearly needed to better understand why rates of VTE prophylaxis remain relatively low and whether the new ACCP guidelines will improve compliance, especially among patients at highest risk (eg, those with multiple risk factors).
